Exploratory study of the expression of the serotonergic 5-HT4 receptor in Parkinson's disease
Key facts
- Where
- BRON cedex és Villeurbanne, FranciaországSee the 2 sites
- Phase
- 2/3. fázis
Where in Franciaország
- CERMEP - imagerie du vivantBRON cedex, FranciaországNo longer taking part
- Hospices Civils De LyonVilleurbanne, FranciaországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospices Civils De Lyon
- Trial code
- EU 2022-503089-57-00
- Record updated
- 2024. május 22.
- Original description
The main objective is to compare the expression of the 5-HT4 receptor in patients with mild to moderate Parkinson's disease compared to age-matched healthy controls (controls)Read full original descriptionShow less
The main objective is to compare the expression of the 5-HT4 receptor in patients with mild to moderate Parkinson's disease compared to age-matched healthy controls (controls)
Inclusion: Clinically established or probable diagnosis of Parkinson's disease according to the criteria defined by the Movement Disorder Society at a Hoehn and Yahr stage ≤ 3 (for patient only); Duration of disease progression between 2 and 8 years (for patient only); MoCA ≥ 20/30 (for patient only); Age between ≥ 50 and ≤ 85 years old; if woman , postmenopausal woman; Affiliated to a social security scheme or similar; Having given their written consent to participate; Level of study: ≥ 6 years of schooling; No history of neurological or psychiatric disease (healthy volunteers only).
Exclusion: Treated with specific serotonin inhibitors (SSRIs), specific noradrenaline inhibitors (SNRIs), tricyclic antidepressants, monoamine oxidase inhibitors (MAOIs) and neuroleptics in the last 3 months; Use of recreational drugs interfering with the serotonergic system (ecstasy, MDMA) or opioids (cannabis, opiates) in the last 3 months or chronic use; Participation in the last year to a study using ionizing radiation or concomitant participation in another research project involving the human being that may interfere with the results or the conclusions of this study; Diagnosis other than Parkinson's disease ( for patient only); Cognitive impairment (MOCA score ≤26) (for healthy volunteers only); Current or past neurological or psychiatric pathology (for healthy volunteers only); Deprivation of liberty by judicial or administrative decision, person subject to a legal protection measure; BMI ≥ 35kg/m2; Presence of depression (BDI-2 score ≥21), anxiety (Parkinson Anxiety Scale, PAS score ≥14) or apathy (STARKSTEIN score ≥14) - for healthy volunteers only; Serious and progressive medical pathology; Contraindication to magnetic resonance imaging (MRI) or positron emission tomography (PET); Exceeding the annual amount of compensation authorized for participation in research protocols.